Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries

Access to recommended second-line treatments is limited for patients who fail initial hepatitis C virus (HCV) therapy in low- and middle-income countries. Alternative regimens and associated outcomes are not well understood. Through a pooled analysis of national program data in Egypt, Georgia, and Myanmar, we observed SVR rates >90% for alternative retreatment regimens.

Automated summary

Access to recommended second-line treatments for patients who fail initial HCV therapy is limited in low- and middle-income countries. However, a pooled analysis of national program data in Egypt, Georgia, and Myanmar showed SVR rates exceeding 90% for alternative retreatment regimens.